… The molecule received orphan drug designation from the FDA in … cancers and autoimmune disease. Ipsen has been picking up licensing … Since 2024, the oncology-focused pharma has signed a $1 billion … Biotechnology on an antibody-drug conjugate to treat solid …

… short-lived benefit, said Ipsen. After the ASCO presentation, … (TCE) therapies from Biomunex Pharma and Marengo Therapeutics last year … cancer pipeline with two antibody-drug conjugate alliances – with … (tovorafenib). Oncology accounted for Ipsen's €1.91 …

Pharma giant Ipsen will pay US$1bn to … gamma delta T cells. Joining Ipsen will accelerate ICT01 toward registrational …

Pharmaceutical company Ipsen has acquired ImCheck Therapeutics, … US Food and Drug Administration and European Medicines Agency in July … promising data combined with Ipsen’s global development and … a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck …

… its strong performance in Q3, Ipsen has announced that it is … ;above 32%'. Likewise, the pharmaceutical company now expects full-year … , and Somatuline. In Q3 alone, Ipsen's sales reached €915m …

Ipsen has announced that it has … orphan drug designation from the US FDA and the European Medicines Agency …

… , and which has received Orphan Drug Designation from the U.S … ; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising … inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability …

… a obtenu la désignation « Orphan Drug Designation » par la Food and … réglementation de l'industrie pharmaceutique et de la législation en … brevets d’Ipsen et d’autres protections concernant les médicaments novateurs ; et …

… the impact of pharmaceutical industry regulation and healthcare legislation and risks arising … in new-medicine development, including obtaining regulatory approval; Ipsen’s ability … of Ipsen’s patents and other protections for innovative medicines; and …